Brasília – The Brazilian market for GLP-1 weight-loss injection pens is poised for significant expansion in 2026 following the expiration of the patent on semaglutide, the active ingredient in Ozempic and Wegovy. With the end of exclusivity expected in March, domestic and international pharmaceutical companies are preparing to launch generic and similar products, a move that analysts estimate could nearly double market revenue from approximately R$11 billion in 2025 to around R$20 billion this year.

Price reductions projected at 30–50% are expected to drive broader demand, although specialists caution that access may remain limited to higher-income segments in the short term. Companies such as EMS, Eurofarma and Hypera are advancing regulatory strategies with Anvisa, which is currently reviewing at least 11 applications for semaglutide-based products and seven for liraglutide. Despite the expected increase in competition, structural barriers and prescription practices are likely to continue shaping the pace and scale of market expansion.

Source: Folha de S.Paulo